By Laura Matthews, Anirban Sen, Manya Saini and Niket Nishant NEW YORK/BENGALURU, May 27 (Reuters) - Prediction market platforms including Kalshi are making a big push to attract top institutional ...

Plans have been submitted to the city council for a school on the site of a former secondary school to be redeveloped.

The AI race is accelerating, and Google is certainly not standing still. At its annual Google I/O developer conference on May ...

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug ...

PhilHealth YAKAP now serves 33.2 million beneficiaries, supported by a growing network of 4,287 accredited primary care ...

Q1 2026 earnings call recap: raised 2026 revenue/EBITDA guidance, DefenCath TDAPA risks, and REZZAYO ReSPECT wins—read now.

President Ferdinand R. Marcos Jr. personally inspects the implementation of enhanced PhilHealth benefits in leading private ...

"We will introduce the 2.4 milligram pemvidutide dose in Phase III," Arbet-Engels said (Chief Medical Officer), describing PERFORMA as "an event-driven study" with "the interim analysis" at "52 weeks ...

The news stacks three catalysts: stronger earnings/free cash flow, a credible enterprise AI product push (“Agentic Enterprise ...

Snowflake has had a rough stretch. The stock is down 21.92% year-to-date and has lost nearly 6% over the past year, according ...

Papzimias: A first-in-class FDA-approved gene therapy indicated for adult patients with recurrent respiratory papillomatosis (RRP), based on a proprietary adenovector technology platform. AdenoVerse ...

Securitization Activity -- Two Non-QM securitizations: a $326 million bond deal with a 5.12% average coupon, and a re-securitization of over $400 million in seasoned loans unlocking $40 million of ...